If you're facing an insurance denial after a provider like Hims moved away from compounded GLP-1s, you have real appeal options — and a cash-pay bridge doesn't have to mean waiting on approval.
Compounded semaglutide ($197/month) and tirzepatide ($297/month) remain available through Luma Health for patients with a documented individual clinical basis, without needing insurance approval.
Many patients researching insurance denial help right now are in a specific situation: they were using a compounded GLP-1 program that's since scaled back or discontinued that offering following the FDA's 2024-2025 shortage resolutions, and they're now trying to access brand-name medication through insurance instead — often for the first time. Here's how that process actually works.
Why More Patients Are Turning to Insurance Now
Following the FDA's determination that the tirzepatide and semaglutide shortages were resolved (December 2024 and February 2025, respectively), the legal basis for widespread cost-driven compounding narrowed considerably, and several telehealth platforms scaled back or discontinued their compounded GLP-1 offerings entirely. Patients who'd been on an affordable compounded plan for months suddenly needed a completely new path — and for many, that means navigating insurance and prior authorization for the first time.
This shift has created a genuinely awkward and often confusing transition for many patients, since navigating prior authorization and appeals is a fundamentally different process than simply paying a flat cash price for compounded medication. Patients accustomed to a straightforward monthly charge sometimes find the insurance process's uncertainty and paperwork burden to be the most frustrating part of the entire transition, more so than the medication itself changing in any meaningful clinical way that would affect their actual treatment outcomes.
It's worth being direct about the practical reality: this transition affects patients across the entire industry, not just those who happened to use Hims specifically, since the underlying regulatory shift applies to any provider engaged in cost-driven compounding regardless of brand name or company size. If you're navigating this shift, you're not alone in finding the insurance process considerably more complicated than the compounded cash-pay model you may have grown accustomed to over the prior year or two.
Common Reasons for Denial
The most frequent denial reasons are: missing documentation of BMI and weight-related comorbidities, a plan-level exclusion of weight-loss medications as a category, a formulary change (some pharmacy benefit managers have shifted preferred GLP-1 products), or a step-therapy requirement to try other treatments first, each of which calls for a different response strategy. Understanding which applies to your specific denial changes what your appeal should focus on.
Reading your denial letter carefully and in full is the essential first step, since insurers are required to state a specific reason, and that reason determines whether an appeal is likely to succeed at all. A documentation gap is usually addressable relatively quickly; a blanket plan-level exclusion generally isn't, since it reflects a plan design decision rather than a case-specific medical judgment about your situation. If your letter doesn't clearly state the reason, you're entitled to request additional clarification directly from your insurer before drafting any formal written appeal on your own behalf.
Building an Effective Appeal
A strong appeal directly addresses the specific reason in your denial letter, and typically includes a letter of medical necessity from your prescribing provider, documentation of your BMI and relevant comorbidities, and reference to your insurer's own coverage criteria showing how you meet them. Published data suggests a meaningful majority of well-documented appeals ultimately succeed in achieving coverage approval. Most commercial plans allow up to 180 days from the date of denial to file an internal appeal — check your specific denial letter for your exact deadline.
If your first-level appeal is denied, most plans allow a second-level internal review, and ERISA-governed employer plans provide a right to external review by an independent reviewer once internal options are fully exhausted. Throughout the process, keep your own record of submission dates and any correspondence you receive, since this documentation makes escalating to a second level or external review considerably more straightforward if it becomes necessary later in the process.
Your prescribing provider's office often has more experience navigating specific insurers' requirements than you might expect, since they submit appeals regularly across many different patients and payers throughout the year. Asking directly whether they have a track record with your specific insurer, or a standard template they use for similar appeals, can meaningfully improve your odds compared to starting entirely from scratch on your own without that institutional knowledge.
Tirzepatide (marketed as Zepbound) carries a separate FDA approval for moderate-to-severe obstructive sleep apnea in adults with obesity. If you have documented or currently suspected sleep apnea, this pathway can sometimes unlock coverage even when a plan otherwise excludes weight-management-only indications.
Raising Coverage Gaps With Your Employer
If your specific denial stems from a blanket plan-level exclusion rather than a documentation issue, an appeal won't change the outcome, since it's a benefit design decision rather than a case-specific determination about your individual medical need. In that situation, raising the exclusion with your employer's HR department is a reasonable next step, particularly since employer benefit decisions are often revisited annually, and enough employee interest can genuinely influence what's included at the next renewal, even if it doesn't help your current situation immediately.
When raising this with HR, framing your request around the broader employee population's likely need for GLP-1 coverage, rather than solely your individual situation, can sometimes carry more weight with a benefits committee that's weighing overall plan costs against employee demand and retention considerations across the full workforce, not just a single employee's specific circumstances.
Bridging the Gap While Insurance Gets Sorted Out
Appeals and prior authorizations can take anywhere from a couple of weeks to well over a month. Rather than pausing treatment during that window, many patients use a cash-pay bridge — either brand-name self-pay pricing (LillyDirect vials for Zepbound commonly run $299-$449/month by dose) or compounded medication through a licensed 503A pharmacy where a genuine individual clinical basis applies. Compounded semaglutide and tirzepatide remain legally available in 2026 under these narrower conditions, even though the blanket cost-driven compounding of the shortage era has ended.
Luma Health's compounded semaglutide ($197/month) and tirzepatide ($297/month) are both structured as flat-rate, cash-pay options with no insurance dependency, making either a reasonable bridge while your appeal or prior authorization plays out elsewhere. If your insurance situation is eventually resolved in your favor, transitioning to insurance-covered brand medication is generally straightforward — share your current dose and treatment history with your new provider so they can continue an appropriate dose rather than restarting titration from the very beginning.
Some patients ultimately choose to stay on the compounded bridge option even after insurance approval comes through, once they've compared the actual total costs directly — a flat monthly compounded price can sometimes come out lower than a branded copay once any separate program fees or deductible contributions are factored in, depending on your specific plan's cost-sharing structure and out-of-pocket maximum for that plan year. It's worth running this comparison honestly for your own numbers rather than assuming insurance coverage automatically means the lowest-cost path forward.
Keeping Your Own Records Throughout
Regardless of which path you take, maintaining your own parallel record of key dates and communications is worth the small effort it takes. Note when you submitted any coverage check, when a prior authorization was filed, and any denial or approval correspondence you receive, including the specific reason cited. If a denial does occur, having this timeline readily available makes putting together an effective appeal considerably easier, since you'll know exactly what's already been submitted and where the specific gap, if any, actually occurred in the process.
This habit is worth maintaining even when things seem to be moving smoothly, since insurance processes can occasionally stall without much notice, and having your own record gives you something concrete to reference if you need to follow up proactively rather than waiting indefinitely for an update that may not come without prompting from your side or a specific follow-up call to your insurer directly.
What to Do Next
Your specific next step depends on which denial reason applies to your situation, whether you have a plan-level exclusion versus a documentation gap, and how much time you're willing to invest in an appeal versus pursuing a cash-pay bridge option in parallel while that process unfolds. Patients facing a straightforward documentation gap often find an appeal worthwhile given the meaningful success rate for well-documented submissions, while patients facing a blanket plan exclusion may find their time better spent pursuing a cash-pay bridge and a longer-term conversation with their employer instead.
- Missing documentation you can now provide
- A step-therapy requirement you can address
- A formulary change where a clinical exception might apply
- You've lost access to a compounded program and need continuity now
- Your plan has a blanket weight-loss exclusion
- You want to avoid a treatment gap while an appeal is pending
Continuity while you
sort out insurance
Compounded semaglutide at $197/month or tirzepatide at $297/month — a real medical evaluation, no insurance approval required.
Get Started → Or start your free health assessmentFrequently Asked Questions
Likely because the FDA's 2024-2025 shortage resolutions narrowed the legal basis for cost-driven compounding, prompting many providers to scale back or discontinue compounded GLP-1 offerings and shift patients toward brand-name, insurance-based options.
Most commercial plans allow up to 180 days from your denial letter, though some plans have shorter windows. Check your specific letter for the exact deadline.
A letter of medical necessity, documentation of BMI and comorbidities, and a direct response to the specific reason cited in your denial letter, referencing your insurer's own coverage criteria.
Possibly. Tirzepatide (Zepbound) has a separate FDA approval for moderate-to-severe obstructive sleep apnea in adults with obesity, which can sometimes unlock coverage even when weight-management-only indications are excluded.
It can be, if there's a genuine documented individual clinical basis for compounding rather than using the commercial product — this is narrower than the blanket cost-driven compounding available during the shortage era, but it remains a legal pathway in 2026.
Most plans allow a second-level review, and employer plans governed by ERISA provide a right to external review by an independent reviewer if internal appeals don't resolve the issue.
An appeal won't change this, since it's a plan design decision rather than a case-specific determination. Raising it with your employer's HR department is a reasonable next step for future plan years.
Many patients do, given that appeals can take a couple of weeks to well over a month. A flat-rate compounded option like Luma Health's can serve as a straightforward bridge without any insurance dependency.
References
- U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. FDA.gov. 2025. FDA.gov
- Malhotra A, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA). N Engl J Med. 2024;391(13):1193-1205. PubMed 38912654
- American Medical Association. Prior authorization resources. AMA-assn.org. AMA-assn.org
- U.S. Food and Drug Administration. Human Drug Compounding and the FD&C Act. FDA.gov. FDA.gov
- Mercer. National Survey of Employer-Sponsored Health Plans, 2025: GLP-1 coverage findings. Mercer.com. 2025. Mercer.com